al. focused on biomarkers with potential (in-) sensitivity to (chemo)-therapeutic agents like taxane and emphasized that a carcinoma-cell based TUBB3 expression predicts the insensitivity to a taxane-based therapy most likely by its ability to keep microtubules in a more dynamic state or influence the drug-binding options ([17–19]). The gene discussed is TUBB3; the disease is carcinoma.